BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22930691)

  • 21. Novel regulators of Fgf23 expression and mineralization in Hyp bone.
    Liu S; Tang W; Fang J; Ren J; Li H; Xiao Z; Quarles LD
    Mol Endocrinol; 2009 Sep; 23(9):1505-18. PubMed ID: 19556340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
    Liu S; Guo R; Simpson LG; Xiao ZS; Burnham CE; Quarles LD
    J Biol Chem; 2003 Sep; 278(39):37419-26. PubMed ID: 12874285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
    Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
    J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of the DMP1 57-kDa functional domain both in vivo and in vitro.
    Lu Y; Qin C; Xie Y; Bonewald LF; Feng JQ
    Cells Tissues Organs; 2009; 189(1-4):175-85. PubMed ID: 18728349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
    Karaplis AC; Bai X; Falet JP; Macica CM
    Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
    Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
    Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Col10a1 expression is not causative for the phenotype of Phex-deficient Hyp mice.
    Yorgan T; Rendenbach C; Jeschke A; Amling M; Cheah KS; Schinke T
    Biochem Biophys Res Commun; 2013 Dec; 442(3-4):209-13. PubMed ID: 24269824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DMP1 Ablation in the Rabbit Results in Mineralization Defects and Abnormalities in Haversian Canal/Osteon Microarchitecture.
    Liu T; Wang J; Xie X; Wang K; Sui T; Liu D; Lai L; Zhao H; Li Z; Feng JQ
    J Bone Miner Res; 2019 Jun; 34(6):1115-1128. PubMed ID: 30827034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
    Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
    Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Function of PHEX mutations p.Glu145* and p.Trp749Arg in families with X-linked hypophosphatemic rickets by the negative regulation mechanism on FGF23 promoter transcription.
    Gan YM; Zhang YP; Ruan DD; Huang JB; Zhu YB; Lin XF; Xiao XP; Cheng Q; Geng ZB; Liao LS; Tang FQ; Luo JW
    Cell Death Dis; 2022 Jun; 13(6):518. PubMed ID: 35654784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
    Xiao L; Du E; Homer-Bouthiette C; Hurley MM
    Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteocytes but not osteoblasts directly build mineralized bone structures.
    Wang K; Ren Y; Lin S; Jing Y; Ma C; Wang J; Yuan XB; Han X; Zhao H; Wang Z; Zheng M; Xiao Y; Chen L; Olsen BR; Feng JQ
    Int J Biol Sci; 2021; 17(10):2430-2448. PubMed ID: 34326685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.
    Liu S; Guo R; Tu Q; Quarles LD
    J Biol Chem; 2002 Feb; 277(5):3686-97. PubMed ID: 11713245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.
    Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO
    Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice.
    Boskey A; Frank A; Fujimoto Y; Spevak L; Verdelis K; Ellis B; Troiano N; Philbrick W; Carpenter T
    Calcif Tissue Int; 2009 Feb; 84(2):126-37. PubMed ID: 19082853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice.
    Courbon G; Kentrup D; Thomas JJ; Wang X; Tsai HH; Spindler J; Von Drasek J; Ndjonko LM; Martinez-Calle M; Lynch S; Hivert L; Wang X; Chang W; Feng JQ; David V; Martin A
    JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37943605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel Phex mutation in a new mouse model of hypophosphatemic rickets.
    Owen C; Chen F; Flenniken AM; Osborne LR; Ichikawa S; Adamson SL; Rossant J; Aubin JE
    J Cell Biochem; 2012 Jul; 113(7):2432-41. PubMed ID: 22573557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.
    Rowe PS
    Cell Biochem Funct; 2012 Jul; 30(5):355-75. PubMed ID: 22573484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteocytes and the pathogenesis of hypophosphatemic rickets.
    Yamazaki M; Michigami T
    Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.